Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99,880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study.
Huo X, Gao L, Guo L, Xu W, Wang W, Zhi X, Li L, Ren Y, Qi X, Sun Z, Li W, Ji Q, Ran X, Su B, Hao C, Lu J, Guo X, Zhuo H, Zhang D, Pan C, Weng J, Hu D, Yang X, Ji L. Huo X, et al. Among authors: li w, li l. Lancet Diabetes Endocrinol. 2016 Feb;4(2):115-24. doi: 10.1016/S2213-8587(15)00508-2. Epub 2015 Dec 17. Lancet Diabetes Endocrinol. 2016. PMID: 26704379
Chinese clinical guidelines for continuous glucose monitoring (2018 edition).
Bao Y, Chen L, Chen L, Dou J, Gao Z, Gao L, Guo L, Guo X, Ji L, Ji Q, Jia W, Kuang H, Li Q, Li Q, Li X, Li Y, Li L, Liu J, Ma J, Ran X, Shi L, Song G, Wang Y, Weng J, Xiao X, Xie Y, Xi G, Yang L, Zhao Z, Zhou J, Zhou Z, Zhu D, Zou D; Chinese Diabetes Society. Bao Y, et al. Among authors: li y, li x, li l, li q. Diabetes Metab Res Rev. 2019 Sep;35(6):e3152. doi: 10.1002/dmrr.3152. Epub 2019 Apr 25. Diabetes Metab Res Rev. 2019. PMID: 30884108 Review.
Standards of medical care for type 2 diabetes in China 2019.
Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, Zou D, Guo L, Ji Q, Chen L, Chen L, Dou J, Guo X, Kuang H, Li L, Li Q, Li X, Liu J, Ran X, Shi L, Song G, Xiao X, Yang L, Zhao Z; Chinese Diabetes Society. Jia W, et al. Among authors: li x, li l, li q. Diabetes Metab Res Rev. 2019 Sep;35(6):e3158. doi: 10.1002/dmrr.3158. Epub 2019 May 29. Diabetes Metab Res Rev. 2019. PMID: 30908791 Review.
Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetes-A multicenter cross-sectional observational study across China.
Zhu Y, Xu F, Shen J, Liu Y, Bi C, Liu J, Li Y, Wang X, Gao Z, Liang L, Chen Y, Sun W, Guan Q, Zhang J, Luo Z, Guo L, Cai X, Li L, Xiu L, Yan L, Li C, Shi X, Zhu M, Kuang J, Li G, Ji L. Zhu Y, et al. Among authors: li c, li y, li g, li l. PLoS One. 2019 May 2;14(5):e0216151. doi: 10.1371/journal.pone.0216151. eCollection 2019. PLoS One. 2019. PMID: 31048873 Free PMC article.
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Zhu D, Gan S, Liu Y, Ma J, Dong X, Song W, Zeng J, Wang G, Zhao W, Zhang Q, Li Y, Fang H, Lv X, Shi Y, Tian H, Ji L, Gao X, Zhang L, Bao Y, Lei M, Li L, Zeng L, Li X, Hou X, Zhao Y, Hu T, Ge X, Zhao G, Li Y, Zhang Y, Chen L. Zhu D, et al. Among authors: li y, li x, li l. Lancet Diabetes Endocrinol. 2018 Aug;6(8):627-636. doi: 10.1016/S2213-8587(18)30105-0. Epub 2018 May 4. Lancet Diabetes Endocrinol. 2018. PMID: 29735394 Clinical Trial.
[The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Pan CY, Li WH, Zeng JE, Li CJ, Yang JK, Ji QH, Lu JM, Lü XF, Li XF, Qu S, Xu XJ, Xue YM, Li L, Jiang ZS, Zheng BZ, Bu RF, Han P, Liu Y, Liu JD, Peng YD, Liu XM, Liu ZM, Yan L, Lei MX, Li XJ, Song QH, Shi BY, Gu W, Li ZF. Pan CY, et al. Among authors: li xf, li wh, li xj, li cj, li l, li zf. Zhonghua Nei Ke Za Zhi. 2013 Nov;52(11):932-5. Zhonghua Nei Ke Za Zhi. 2013. PMID: 24439186 Clinical Trial. Chinese.
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Pan C, Li W, Zeng J, Li C, Yang J, Ji Q, Lu J, Lyu X, Li X, Qu S, Xu X, Xue Y, Li L, Jiang Z, Zheng B, Bu R, Han P, Liu Y, Liu J, Peng Y, Liu X, Liu Z, Yan L, Lei M, Li X, Song Q, Shi B, Gu W, Li Z. Pan C, et al. Among authors: li c, li z, li w, li x, li l. Zhonghua Nei Ke Za Zhi. 2015 Nov;54(11):949-53. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26759214 Clinical Trial. Chinese.
99,880 results
You have reached the last available page of results. Please see the User Guide for more information.